BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $10.29B
• Dividend Yield: N/A
• Average Volume (3M): 2.52M
• Price to Earnings (P/E): 20.1
• Beta (1Y): 0.45
• Revenue Growth: 12.31%
• EPS Growth: 60.21%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 192,114,350
• 10 Day Avg. Volume: 3,315,200
• 30 Day Avg. Volume: 2,524,344
• PEG Ratio: 0.19
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 4.38
• P/FCF Ratio: 26.27
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 3.08
• Enterprise Value/Gross Profit: 3.79
• Enterprise Value/Ebitda: 12.34
• 1Y Price Target: $91.20
• Price Target Upside: 70.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 22

• Rating: 73 Outperform
• Price Target: $59.00 ▲(10.14% Upside)

BioMarin Pharmaceutical's strong financial performance and positive earnings call sentiment are key strengths, supported by robust revenue growth and operational efficiency. However, the bearish technical indicators and challenges highlighted in the earnings call, such as the IPR&D charge and ROCTAVIAN divestment, temper the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product adoption, supporting long-term business expansion and sustainability.

Pipeline Progress

Advancements in the pipeline, like BMN 333, demonstrate BioMarin's commitment to innovation and potential for future product launches, enhancing competitive positioning.

Cash Flow Management

Strong cash flow growth and management provide financial flexibility for strategic investments and operational stability, supporting long-term growth.

Negative Factors

Increased Operating Expenses

Rising operating expenses could pressure margins and profitability, potentially impacting financial performance if not offset by revenue growth.

Potential Lower Profitability in Q3

Anticipated lower profitability in Q3 due to increased expenses may affect short-term financial results, posing a challenge to maintaining margin improvements.

VOXZOGO Revenue Guidance Adjustment

Adjusting VOXZOGO's revenue guidance suggests potential challenges in meeting sales expectations, which could impact overall revenue targets and investor confidence.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin generates revenue primarily through the sale of its pharmaceutical products, which are targeted at rare diseases. Key revenue streams include the sale of its approved therapies, such as Vimizim (elosulfase alfa), Brineura (cerliponase alfa), and Kuvan (sapropterin dihydrochloride). Additionally, the company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to enhance its research capabilities and expand its market reach. These partnerships may involve co-development agreements, licensing fees, and milestone payments that contribute to BioMarin's earnings. The company's focus on rare diseases often allows it to command higher prices for its specialized treatments, further bolstering its revenue.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates strong financial health with impressive revenue and profit growth, efficient cost management, and a solid balance sheet. The company is well-positioned in the biotechnology industry, with low leverage and strong cash flow generation, which provides a stable foundation for future growth.

Income Statement

BioMarin Pharmaceutical has shown impressive revenue growth, with a TTM growth rate of 99.2%. The company maintains strong profitability metrics, with a gross profit margin of 79.6% and a net profit margin of 21.5% in the TTM. The EBIT and EBITDA margins have also improved significantly over the years, indicating efficient cost management and operational performance.

Balance Sheet

The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.10, indicating conservative leverage. The return on equity has improved to 11.5% in the TTM, showcasing enhanced profitability. The equity ratio stands at a healthy level, suggesting a strong capital structure.

Cash Flow

Cash flow analysis reveals robust growth in free cash flow, with a 20.2% increase in the TTM. The operating cash flow to net income ratio is strong at 1.12, indicating efficient cash generation relative to earnings. The free cash flow to net income ratio of 0.90 further underscores the company's ability to convert profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.09B	2.85B	2.42B	2.10B	1.85B	1.86B
Gross Profit	2.52B	2.27B	1.89B	1.59B	1.38B	1.34B
EBITDA	772.37M	650.53M	306.77M	265.36M	47.43M	83.66M
Net Income	520.42M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet
Total Assets	7.61B	6.99B	6.84B	6.38B	6.00B	5.85B
Cash, Cash Equivalents and Short-Term Investments	1.48B	1.14B	1.07B	1.29B	1.01B	1.07B
Total Debt	596.66M	633.97M	1.10B	1.09B	1.09B	1.09B
Total Liabilities	1.56B	1.33B	1.89B	1.77B	1.74B	1.74B
Stockholders Equity	6.06B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow
Free Cash Flow	831.36M	475.42M	51.65M	44.36M	185.31M	-52.15M
Operating Cash Flow	913.98M	572.84M	159.26M	175.90M	304.54M	85.36M
Investing Cash Flow	-295.39M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
Financing Cash Flow	-42.69M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Neutral. The current price of 53.57 is above the 20-day moving average (MA) of 53.41, below the 50-day MA of 54.78, and below the 200-day MA of 59.93, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 49.27 is Neutral, neither overbought nor oversold. The STOCH value of 20.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	―	$18.35B	15.68	30.39%	―	18.09%	3563.21%
UTHR	―	$19.18B	16.88	20.04%	―	13.50%	17.16%
EXEL	―	$10.41B	18.55	29.00%	―	10.73%	81.66%
GMAB	―	$17.48B	14.17	26.08%	―	23.25%	64.46%
BMRN	―	$10.29B	20.07	9.07%	―	12.31%	60.21%
ASND	―	$12.21B	-40.58	―	―	55.77%	46.81%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioMarin Pharmaceutical Corporate Events

Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth

Biomarin Pharmaceutical Inc.’s strategy of pursuing acquisitions, such as the recent purchase of Inozyme, presents significant business risks. These acquisitions could divert management’s focus and incur substantial costs, potentially leading to challenges in integrating operations and realizing anticipated benefits. The integration process may face hurdles like cultural misalignment and operational disruptions, which could impact relationships with key stakeholders and affect financial performance. Additionally, the success of acquired product candidates is uncertain, possibly requiring more resources and not delivering expected synergies, thus adversely affecting Biomarin’s growth prospects.

BioMarin’s Earnings Call: Growth Amid Challenges

BioMarin Pharmaceutical Inc.’s recent earnings call painted a picture of both triumphs and challenges. The company reported robust revenue growth, particularly driven by VOXZOGO and enzyme therapies, alongside a strong cash position and operational efficiency. However, the call also highlighted significant hurdles, such as a substantial IPR&D charge and the decision to divest ROCTAVIAN, which balanced the overall sentiment.

BioMarin Reports Strong Q3 2025 Revenue Growth

BioMarin Pharmaceutical Inc. is a biotechnology company based in San Rafael, California, specializing in developing and commercializing therapies for rare genetic diseases. The company is known for its innovative approach to drug discovery and development, with a focus on genetically defined conditions.

BioMarin’s BMN 349 Study: A New Hope for Alpha 1-Antitrypsin Deficiency

BioMarin Pharmaceutical Inc. is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)’. The study aims to evaluate the safety and pharmacokinetics of BMN 349, a potential treatment for Alpha 1-Antitrypsin Deficiency, an inherited condition that can lead to lung and liver disease.

BioMarin’s Vosoritide Study: A Potential Game-Changer for Hypochondroplasia Treatment

BioMarin Pharmaceutical Inc. is conducting a clinical study titled ‘A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months.' The study aims to assess the safety and efficacy of vosoritide, a drug administered daily to children with hypochondroplasia, a genetic disorder affecting bone growth.

BioMarin’s Vosoritide Study: A Potential Game-Changer in Pediatric Growth Disorders

BioMarin Pharmaceutical Inc. is conducting a Phase 2 basket study titled ‘A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With an Inadequate Response to Human Growth Hormone.’ The study aims to assess the efficacy of vosoritide, a modified recombinant human C-type natriuretic peptide, in improving growth in children with these conditions compared to human growth hormone (hGH) treatment.

BioMarin’s Long-Term Study on BMN 270: A Potential Game Changer for Hemophilia A

BioMarin Pharmaceutical Inc. is conducting a long-term follow-up study titled ‘A Long-Term Follow-Up Study in Subjects With Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial.’ The study aims to evaluate the long-term safety and efficacy of BMN 270, a gene therapy for severe Hemophilia A, over a period extending beyond five years post-infusion. This research is significant for understanding the durability of the treatment’s effects.

BioMarin’s Vosoritide Study: A Long-Term Hope for Hypochondroplasia

BioMarin Pharmaceutical Inc. is conducting a Phase 3, open-label, long-term extension study titled ‘A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia.’ The study aims to assess the long-term safety and efficacy of daily doses of vosoritide in children diagnosed with hypochondroplasia, a genetic disorder affecting bone growth.

BioMarin’s BMN 351 Study: A New Hope for Duchenne Muscular Dystrophy

BioMarin Pharmaceutical Inc. is conducting a Phase 1/2 study titled A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy. The study aims to evaluate the safety and tolerability of BMN 351 in patients with Duchenne Muscular Dystrophy (DMD) who have a genetic mutation suitable for exon 51 skipping. This research is significant as it targets a severe genetic disorder with limited treatment options.

BioMarin’s Observational Study on Idiopathic Short Stature: Key Insights for Investors

BioMarin Pharmaceutical Inc. is conducting a study titled ‘A Multicenter, Observational Study to Characterize Growth in Children With Idiopathic Short Stature.’ The study aims to gather baseline growth data in children diagnosed with idiopathic short stature (ISS) by collecting various growth measurements and related variables. This research is significant as it seeks to better understand growth patterns in children with ISS, potentially leading to improved treatment strategies.

BioMarin’s Observational Study on Hypochondroplasia: Key Insights for Investors

Study Overview: BioMarin Pharmaceutical Inc. is conducting a study titled A Multicenter Multinational Observational Study of Children With Hypochondroplasia. The study aims to assess growth and the clinical progression of hypochondroplasia (HCH) in children by collecting growth measurements and other relevant data. This research is significant as it seeks to enhance understanding of HCH, potentially informing future treatments.

BioMarin’s VISTA Study: A New Chapter in Achondroplasia Treatment

BioMarin Pharmaceutical Inc. has launched a new study titled ‘VIrtual STudy in Achondroplasia for the US (VISTA)’ to observe individuals with achondroplasia in the United States. The study aims to gather data on pediatric individuals, both treated and untreated with VOXZOGO™, to better understand the real-life treatment use and clinical care. This research is significant as it could lead to improved treatment strategies for achondroplasia.

BioMarin’s New Study on Rapid Drug Desensitization for Palynziq: What Investors Need to Know

BioMarin Pharmaceutical Inc. is conducting a Phase 4 clinical study titled ‘A Phase 4 Study to Evaluate the Impact of a Rapid Drug Desensitization (RDD) Protocol for Adults with Phenylketonuria and Experiencing Hypersensitivity Reactions to Palynziq.’ The study aims to assess whether a rapid drug desensitization protocol can enhance drug tolerability and treatment persistence in adult patients with phenylketonuria who experience hypersensitivity reactions to Palynziq, potentially leading to treatment interruptions.

BioMarin’s Vosoritide Study: A New Hope for Children with Idiopathic Short Stature

BioMarin Pharmaceutical Inc. is conducting a Phase 2, randomized, controlled, multicenter study titled ‘A Phase 2 Study of Vosoritide in Children with Idiopathic Short Stature.’ The study aims to evaluate the effects of multiple doses of vosoritide and compare its therapeutic dose to human growth hormone (hGH) in children with idiopathic short stature (ISS). This research is significant as it explores potential new treatments for ISS, which could offer alternatives to existing therapies.

BioMarin Announces Resignation of Chief Accounting Officer

On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.

The most recent analyst rating on (BMRN) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin’s Earnings Call: Growth Amid Challenges

BioMarin Pharmaceutical Inc. recently held its earnings call, revealing a mix of positive growth and operational challenges. The company reported significant revenue growth and strategic acquisitions, yet it faces hurdles with rising expenses and adjusted revenue expectations for VOXZOGO. While BioMarin’s performance and future outlook remain strong, these operational challenges add a layer of caution to their otherwise optimistic narrative.

BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results

BioMarin Pharmaceutical Inc., a biotechnology company based in San Rafael, California, focuses on developing and commercializing innovative therapies for rare genetic conditions. Founded in 1997, BioMarin has a strong portfolio of eight commercial therapies and a robust pipeline of clinical and preclinical candidates.

BioMarin Expands Board with New Director Appointment

On July 30, 2025, BioMarin Pharmaceutical‘s Board of Directors expanded from ten to eleven members, appointing Ian T. Clark effective August 1, 2025. Mr. Clark joins the Audit and Science and Technology Committees, receiving standard director fees and a $400,000 restricted stock unit grant. This strategic move aims to strengthen BioMarin’s governance and oversight, potentially enhancing its industry positioning and stakeholder confidence.

The most recent analyst rating on (BMRN) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.